Cutia Therapeutics (HKG:2487) said its CU-40102 topical finasteride spray received marketing approval from Macao's Pharmaceutical Administration Bureau for the treatment of androgenetic alopecia, according to a Monday Hong Kong bourse filing.
The approval follows marketing authorizations from China's National Medical Products Administration and Hong Kong's Department of Health.